600079 人福医药
2025/09 - 九个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入17,883,352-6.58%25,435,48424,524,74122,337,71920,548,930
减:营业总成本15,280,235-8.19%22,665,86821,417,05919,851,77518,750,613
    其中:营业成本9,308,722-8.67%14,103,26113,290,99212,615,13811,764,845
               财务费用212,607-35.04%350,704304,519236,944623,308
               资产减值损失(18,194)328.19%(393,861)(61,407)(88,312)(55,124)
公允价值变动收益(3,042)-58.09%112,717136,85543,4177,885
投资收益59,393-26.20%133,086206,785835,557306,009
    其中:对联营企业和合营企业的投资收益59,62621.84%68,16159,99222,514132,336
营业利润2,698,7771.62%2,522,0293,447,1743,516,0282,249,040
利润总额2,631,6611.65%2,422,8303,383,8293,426,0532,172,974
减:所得税费用448,539-6.87%644,487568,563354,751354,782
净利润2,183,1223.59%1,778,3432,815,2663,071,3021,818,193
减:非控股权益494,545-4.47%448,598680,781587,194501,047
股东净利润1,688,5776.22%1,329,7452,134,4852,484,1091,317,146

市场价值指针
每股收益 (元) *1.0305.10%0.8201.3201.5400.830
每股派息 (元) *----0.4700.4600.1600.150
每股净资产 (元) *11.5885.85%10.79710.4419.2107.929
审计意见 #--带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见标准无保留意见标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容